OpGen, Inc. (OPGN) News

OpGen, Inc. (OPGN): $0.12

-0.01 (-7.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter OPGN News Items

OPGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

OPGN News Highlights

  • OPGN's 30 day story count now stands at 2.
  • Over the past 1 day, the trend for OPGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • AMR, AMP and UTI are the most mentioned tickers in articles about OPGN.

Latest OPGN News From Around the Web

Below are the latest news stories about OPGEN INC that investors may wish to consider to help them evaluate OPGN as an investment opportunity.

OpGen, Inc. (OPGN) Q3 2022 Earnings Call Transcript

OpGen, Inc. (OPGN)

Q3 2022 Earnings Conference Call

November 10, 2022 16:30 ET

Company Participants

Alyssa Factor - Investor Relations Associate, Edison Group

Oliver Schacht - President & Chief Executive Officer

Albert Weber - Chief Financial Officer

Conference Call Participants

Presentation

Operator

Welcome to the OpGen Third Quarter 2022 Earnings Call and Business Update. Today, OpGen management will provide an update on the company's current business and outlook for the future. Following options prepared remarks, there will be a live Q&A Session. As a reminder, this conference call is being recorded today November 10 2022, and all participants are...

SA Transcripts on Seeking Alpha | November 11, 2022

OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update

Completes first two commercial customer installations for Acuitas AMR Gene PanelOpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with FIND for the Unyvero A30 RQ platformElects Yvonne Schlaeppi as new, independent non-executive director to the boardManagement conference call scheduled for November 10, 2022, at 4:30 p.m. EST ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision

Yahoo | November 10, 2022

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update

Preliminary Total Revenue for Q3 2022 was approximately $0.4 millionCash as of September 30, 2022 was approximately $10.3 million and as of October 3, 2022 was approximately $13.3 millionAdditional customer contract for Acuitas AMR Gene Panel signed in Q3 2022 ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that to

Yahoo | October 27, 2022

OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time

ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Standard Time to discuss the Company’s financial results and provide an update on business activities. Con

Yahoo | October 27, 2022

OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support

Unyvero platform for rapid diagnostics to be used in Phase II clinical trial of BV100Focus on the detection of pneumonia patients infected with Acinetobacter baumannii ROCKVILLE, Md. and BASEL, Switzerland, Oct. 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, and BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmac

Yahoo | October 25, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time for another dive into the biggest pre-market stock movers as we get a start on Thursday trading with the latest news!

William White on InvestorPlace | October 20, 2022

OpGen Announces Closing of $3.38 Million Registered Direct Offering

ROCKVILLE, Md., Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has closed its previously announced registered direct offering with a single institutional investor for the purchase and sale of 9,660,000 shares of the Company’s common stock (or common stock equivalents), 33,810 shares of Series C mirroring

Yahoo | October 3, 2022

OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

Prospective multicenter trial for the Unyvero UTI Panel has successfully completed enrollment of patient samplesUrine samples have been collected from over 1,800 patients at 4 U.S. clinical trial sitesClinical performance evaluation aims at a subsequent FDA submission ROCKVILLE, Md., Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease

Yahoo | October 3, 2022

OpGen Announces $3.38 Million Registered Direct Offering

ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale in a registered direct offering of 9,660,000 shares of the Company’s common stock (or common stock equivalents), 33,810 shares of

Yahoo | September 30, 2022

OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform

FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low and middle income countries (LMICs)Initial project focuses on feasibility study for the rapid detection of antimicrobial resistance (AMR) markers from blood cultureFeasibility phase of R&D project set to conclude by the end of Q1-2023 and co-funded by FIND with euro 700,000 ROCKVILLE, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Co

Yahoo | September 20, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7138 seconds.